


### Claims

1. A compound of the formula:



wherein

A<sup>1</sup> is a D- or L-isomer of an aromatic amino acid, or is deleted;

A<sup>2</sup> is a D-isomer selected from the group consisting of Cys, Pen, an aromatic amino acid, or an aliphatic amino acid;

A<sup>3</sup> is an aromatic amino acid;

A<sup>4</sup> is Trp or D-Trp;

A<sup>6</sup> is Thr, Thr(Bzl), Gly, Ser, an Eaa, or an aliphatic amino acid;

A<sup>7</sup> is Cys, Pen, or an aromatic or an aliphatic amino acid;

A<sup>8</sup> is a D- or L-isomer selected from the group consisting of Thr, Ser, an aromatic amino acid, or an aliphatic amino acid;

each of R<sub>1</sub> and R<sub>2</sub>, is, independently, H or substituted or unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle, heterocycle lower alkyl, E<sub>1</sub>SO<sub>2</sub> or E<sub>1</sub>CO (where E<sub>1</sub> is aryl, aryl lower alkyl, heterocycle, or heterocycle lower alkyl), where said substituent is halo, lower alkyl, hydroxy, halo lower alkyl, or hydroxy lower alkyl; and

R<sub>3</sub> is OH, NH<sub>2</sub>, C<sub>1-12</sub> alkoxy, or NH-Y-CH<sub>2</sub>-Z, wherein Y is a C<sub>1-12</sub> hydrocarbon moiety and Z is H, OH, CO<sub>2</sub>H, or CONH<sub>2</sub>, or R<sub>3</sub>, together with the carbonyl group of A<sup>8</sup> attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl; provided if A<sup>2</sup> is D-Cys or D-Pen, and A<sup>7</sup> is Cys or Pen, then a disulfide bond links the sidechains of A<sup>2</sup> and A<sup>7</sup>, and if A<sup>1</sup> is

34 D-Phe or p-NO<sub>2</sub>-Phe; A<sup>2</sup> is D-Cys; A<sup>3</sup> is Phe or Tyr; A<sup>6</sup> is Thr or  
35 Val; and A<sup>7</sup> is Cys; then A<sup>8</sup> is β-Nal.

1           2.     A compound of claim 1, wherein A<sup>2</sup> is D-Cys, A<sup>7</sup> is  
2 Cys, and A<sup>4</sup> is D-Trp.

1           3.     A compound of claim 2, wherein A<sup>1</sup> is an L-  
2 aromatic amino acid.

1           4.     A compound of claim 3, wherein A<sup>1</sup> and A<sup>3</sup>,  
2 independently, is β-Nal, o-X-Phe (where X is H, OH, CH<sub>3</sub>, halo,  
3 OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe (where X is H, OH, CH<sub>3</sub>, halo,  
4 OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe (where X is H, OH, CH<sub>3</sub>, halo,  
5 OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His,  
6 Igl, Tyr(I), Bta, Bip, Npa, or Pal; A<sup>6</sup> is Thr, Ser, Tle,  
7 Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, β-Ala, Gaba, or Val;  
8 and A<sup>8</sup> is the D- or L-isomer of Thr, Dip, F<sub>5</sub>-Phe, p-X-Phe  
9 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), o-X-Phe  
10 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe  
11 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), Igl,  
12 Tyr(Bzl), or β-Nal.

1           5.     A compound of claim 4, wherein A<sup>1</sup> is β-Nal, Npa,  
2 Igl, Phe, p-F-Phe, Trp, p-Cl-Phe, or p-CN-Phe; A<sup>3</sup> is Tyr,  
3 Tyr(I), or Pal; A<sup>6</sup> is Val, Tle, Nle, Ile, or Leu; A<sup>8</sup> is p-F-  
4 Phe, β-Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-Phe; R<sub>1</sub> is H,  
5 CH<sub>3</sub>CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-  
6 hydroxyethyl)-1-piperazineethanesulfonyl; R<sub>2</sub> is H; and R<sub>3</sub> is  
7 NH<sub>2</sub>.

1           6.     A compound of claim 5, wherein A<sup>3</sup> is Pal.

2           7.     A compound of claim 4 of the formula:

3           H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
4           (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>  
5           (V);

6 (H) - (4 - (2-hydroxyethyl) - 1-piperazinylacetyl) -  $\beta$ -Nal-D-  
 7 Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 8 (H) - (4 - (2-hydroxyethyl) - 1-piperizineethanesulfonyl) -  $\beta$ -  
 9 Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 10 H<sub>2</sub>- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 11 (H) (CH<sub>3</sub>CO) -  $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 12 (H) - (4 - (2-hydroxyethyl) - 1-piperazinylacetyl) -  $\beta$ -Nal-D-  
 13 Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 14 (H) - (4 - (2-hydroxyethyl) - 1-piperizineethanesulfonyl) -  $\beta$ -  
 15 Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 16 H<sub>2</sub>- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 17 (H) (CH<sub>3</sub>CO) -  $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 18 (H) (4 - (2-hydroxyethyl) - 1-piperazinylacetyl) -  $\beta$ -Nal-D-  
 19 Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 20 (H) (4 - (2-hydroxyethyl) - 1-piperizineethanesulfonyl) -  $\beta$ -  
 21 Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 22 H<sub>2</sub>- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 23 (H) (CH<sub>3</sub>CO) -  $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 24 (H) (4 - (2-hydroxyethyl) - 1-piperazinylacetyl) -  $\beta$ -Nal-D-  
 25 Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 26 (H) (4 - (2-hydroxyethyl) - 1-piperizineethanesulfonyl) -  $\beta$ -  
 27 Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 28 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 29 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 30 (H) (4 - (2-hydroxyethyl) - 1-piperazinylacetyl) - Phe-D-Cys-  
 31 Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 32 (H) (4 - (2-hydroxyethyl) - 1-piperizineethanesulfonyl) - Phe-  
 33 D-Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 34 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 35 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 36 (H) (4 - (2-hydroxyethyl) - 1-piperazinylacetyl) - Phe-D-Cys-  
 37 Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 38 (H) (4 - (2-hydroxyethyl) - 1-piperizineethanesulfonyl) - Phe-  
 39 D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
 40 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;

41 (H) (CH<sub>3</sub>CO) - Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 42 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - Phe-D-Cys-  
 43 Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 44 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - Phe-  
 45 D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 46 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 47 (H) (CH<sub>3</sub>CO) - β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 48 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
 49 Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 50 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - β-  
 51 Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 52 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 53 (H) (CH<sub>3</sub>CO) - β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 54 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
 55 Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 56 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - β-  
 57 Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 58 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 59 H(CH<sub>3</sub>CO) - β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 60 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
 61 Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 62 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - β-  
 63 Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 64 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 65 (H) (CH<sub>3</sub>CO) - β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 66 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
 67 Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 68 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - β-  
 69 Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 70 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 71 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 72 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-  
 73 Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 74 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) Phe-  
 75 D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;

76 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 77 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 78 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-  
 79 Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 80 (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-  
 81 D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 82 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 83 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 84 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-  
 85 Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 86 (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-  
 87 D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 88 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 89 (H) (CH<sub>3</sub>CO) -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 90 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-  
 91 Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 92 (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-  
 93 D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 94 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;  
 95 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;  
 96 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;  
 97 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;  
 98 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>;  
 99 H<sub>2</sub>-Phe-D-Pen-Tyr-D-Trp-Lys-Val-Pen-β-Nal-NH<sub>2</sub>; or  
 100 H<sub>2</sub>-Phe-D-Pen-Pal-D-Trp-Lys-Thr-Pen-Thr-NH<sub>2</sub>;  
 101 H<sub>2</sub>-Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys-Dip-NH<sub>2</sub>;  
 102 H<sub>2</sub>-F<sub>5</sub>-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-F<sub>5</sub>-Phe-NH<sub>2</sub>;  
 103 H<sub>2</sub>-Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 104 H<sub>2</sub>-m-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-m-F-Phe-NH<sub>2</sub>;  
 105 H<sub>2</sub>-o-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-o-F-Phe-NH<sub>2</sub>;  
 106 H<sub>2</sub>-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-p-F-Phe-NH<sub>2</sub>;  
 107 H<sub>2</sub>-F<sub>5</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-F<sub>5</sub>-Phe-NH<sub>2</sub>;  
 108 H<sub>2</sub>-F<sub>5</sub>-Phe-D-Cys-2-Pal-D-Trp-Lys-Val-Cys-F<sub>5</sub>-Phe-NH<sub>2</sub>;  
 109 H<sub>2</sub>-β-Nal-D-Cys-His-D-Trp-Lys-Val-Cys-Dip-NH<sub>2</sub>;  
 110 H<sub>2</sub>-Dip-D-Cys-His-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;

111 H<sub>2</sub>-Dip-D-Cys-His-D-Trp-Lys-Val-Cys-Dip-NH<sub>2</sub>;  
 112 H<sub>2</sub>-β-Nal-D-Cys-His-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 113 H<sub>2</sub>-Trp-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-β-Nal-NH<sub>2</sub>;  
 114 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-β-Nal-NH<sub>2</sub>;  
 115 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-p-F-Phe-NH<sub>2</sub>;  
 116 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
 117 H<sub>2</sub>-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 118 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Nle-Cys-β-Nal-NH<sub>2</sub>;  
 119 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Ile-Cys-β-Nal-NH<sub>2</sub>;  
 120 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Gly-Cys-β-Nal-NH<sub>2</sub>;  
 121 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Ala-Cys-β-Nal-NH<sub>2</sub>;  
 122 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Leu-Cys-β-Nal-NH<sub>2</sub>;  
 123 H<sub>2</sub>-Bip-D-Cys-Tyr-D-Trp-Lys-Ile-Cys-Bip-NH<sub>2</sub>;  
 124 H<sub>2</sub>-p-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-p-F-Phe-NH<sub>2</sub>;  
 125 H<sub>2</sub>-Npa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Tyr-NH<sub>2</sub>;  
 126 H<sub>2</sub>-m-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-m-F-Phe-NH<sub>2</sub>;  
 127 H<sub>2</sub>-o-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-o-F-Phe-NH<sub>2</sub>;  
 128 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Dip-NH<sub>2</sub>;  
 129 H<sub>2</sub>-Cpa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Cpa-NH<sub>2</sub>;  
 130 H<sub>2</sub>-Igl-D-Cys-Pal-D-Trp-Lys-Val-Cys-Igl-NH<sub>2</sub>;  
 131 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-Dip-NH<sub>2</sub>;  
 132 H<sub>2</sub>-β-Nal-D-Cys-3-I-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 133 H<sub>2</sub>-p-CN-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-p-CN-Phe-NH<sub>2</sub>;  
 134 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-Dip-NH<sub>2</sub>;  
 135 H<sub>2</sub>-β-Nal-D-Cys-Bta-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 136 H<sub>2</sub>-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
 137 H<sub>2</sub>-Bpa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Bpa-NH<sub>2</sub>;  
 138 H<sub>2</sub>-Iph-D-Cys-Pal-D-Trp-Lys-Val-Cys-Iph-NH<sub>2</sub>;  
 139 H<sub>2</sub>-Trp-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
 140 H<sub>2</sub>-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 141 H<sub>2</sub>-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
 142 H<sub>2</sub>-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-p-Cl-Phe-NH<sub>2</sub>;  
 143 H<sub>2</sub>-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Cha-Cys-p-Cl-Phe-NH<sub>2</sub>;  
 144 H<sub>2</sub>-p-Cl-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Val-Cys-p-Cl-Phe-  
 145 NH<sub>2</sub>;

146 H<sub>2</sub>-p-Cl-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 147 H<sub>2</sub>-p-Cl-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
 148 H<sub>2</sub>-p-F-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 149 H<sub>2</sub>-p-F-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
 150 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;  
 151 (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;  
 152 H<sub>2</sub>-p-NO<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;  
 153 (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;  
 154 H<sub>2</sub>-p-NO<sub>2</sub>-Phe-D-Cys-Tyr(Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-β-  
 155 Nal-NH<sub>2</sub>;  
 156 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-p-NO<sub>2</sub>-Phe-  
 157 D-Cys-Tyr(Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-β-Nal-NH<sub>2</sub>;  
 158 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-p-NO<sub>2</sub>-Phe-  
 159 D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Tyr-NH<sub>2</sub>;  
 160 H<sub>2</sub>-p-NO<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 161 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-p-NO<sub>2</sub>-Phe-  
 162 D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 163 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-Phe-  
 164 D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 165 H<sub>2</sub>-β-Nal-D-Cys-Tyr(Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-β-Nal-  
 166 NH<sub>2</sub>; or  
 167 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
 168 Cys-Tyr(Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-Tyr(Bzl)-NH<sub>2</sub>; or  
 169 a pharmaceutically acceptable salt thereof.

1           8.     A compound of claim 2, wherein A<sup>1</sup> is a D-aromatic  
 2 amino acid.

1           9.     A compound of claim 8, wherein A<sup>1</sup> is D-β-Nal, D-  
 2 o-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-  
 3 p-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-  
 4 m-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-  
 5 F<sub>3</sub>-Phe, D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-  
 6 Tyr(I), D-Bta, D-Bip, D-Npa, or D-Pal; A<sup>3</sup> is β-Nal, o-X-Phe  
 7 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe

8 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe  
 9 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe,  
 10 Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or  
 11 Pal; A<sup>6</sup> is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly,  
 12 Nle, β-Ala, Gaba, or Val; and A<sup>8</sup> is the D- or L-isomer of Thr,  
 13 Dip, F<sub>5</sub>-Phe, p-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>,  
 14 CN, or NO<sub>2</sub>), o-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>,  
 15 CN, or NO<sub>2</sub>), m-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>,  
 16 CN, or NO<sub>2</sub>), Igl, Tyr(Bzl), or β-Nal.

1 10. A compound of claim 9, wherein A<sup>1</sup> is D-β-Nal, D-  
 2 Npa, D-Igl, D-Phe, D-p-F-Phe, D-Trp, D-p-Cl-Phe, or D-p-  
 3 CN-Phe; A<sup>3</sup> is Tyr, Tyr(I), or Pal; A<sup>6</sup> is Val, Tle, Nle, Ile, or  
 4 Leu; A<sup>8</sup> is p-F-Phe, β-Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-  
 5 Phe; R<sub>1</sub> is H, CH<sub>3</sub>CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or  
 6 4-(2-hydroxyethyl)-1-piperizineethanesulfonyl; R<sub>2</sub> is H; and R<sub>3</sub>  
 7 is NH<sub>2</sub>.

1 11. A compound of claim 10, wherein A<sup>3</sup> is Pal.

1 12. A compound of claim 8, of the formula:  
 2 H<sub>2</sub>-D-Phe-D-Pen-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 3 H<sub>2</sub>-D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
 4 H<sub>2</sub>-D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 5 H<sub>2</sub>-D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
 6 H<sub>2</sub>-D-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
 7 H<sub>2</sub>-D-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>;  
 8 H<sub>2</sub>-D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>;  
 9 H<sub>2</sub>-D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-β-Nal-NH<sub>2</sub>;  
 10 H<sub>2</sub>-D-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-p-F-Phe-NH<sub>2</sub>;  
 11 H<sub>2</sub>-D-Bip-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 12 H<sub>2</sub>-D-Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
 13 H<sub>2</sub>-D-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
 14 H<sub>2</sub>-D-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-p-Cl-Phe-NH<sub>2</sub>;



15 p-NO<sub>2</sub>-D-Phe-D-Cys-Pal-D-Trp-Lys-Thr(Bzl)-Cys-Tyr(Bzl)-  
16 NH<sub>2</sub>;

17 p-NO<sub>2</sub>-D-Phe-D-Cys-Tyr(Bzl)-D-Trp-Lys-Val-Cys-Tyr(Bzl)-  
18 NH<sub>2</sub>;

19 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-p-NO<sub>2</sub>-D-  
20 Phe-D-Cys-Pal-D-Trp-Lys-Thr(Bzl)-Cys-Tyr(Bzl)-NH<sub>2</sub>; or

21 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-p-NO<sub>2</sub>-D-  
22 Phe-D-Cys-Tyr(Bzl)-D-Trp-Lys-Val-Cys-Tyr(Bzl)-NH<sub>2</sub>; or

23 a pharmaceutically acceptable salt thereof.

24 13. A compound of claim 2, wherein A<sup>1</sup> is deleted, R<sup>1</sup>  
25 is substituted or unsubstituted E<sub>1</sub>CO, and R<sub>2</sub> is H.

1 14. A compound of claim 13, wherein R<sub>1</sub> is substituted  
2 or unsubstituted E<sub>1</sub>CO (where E<sub>1</sub> is phenyl, β-naphthylmethyl, β-  
3 pyridinylmethyl, or 3-indolylmethyl); A<sup>3</sup> is β-Nal, o-X-Phe  
4 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe  
5 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe  
6 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe,  
7 Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or  
8 Pal; A<sup>6</sup> is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly,  
9 Nle, β-Ala, Gaba, or Val; and A<sup>8</sup> is the D- or L-isomer of Thr,  
10 Dip, F<sub>5</sub>-Phe, p-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>,  
11 CN, or NO<sub>2</sub>), o-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>,  
12 CN, or NO<sub>2</sub>), m-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>,  
13 CN, or NO<sub>2</sub>), Igl, Tyr(Bzl), or β-Nal.

1 15. A compound of claim 14, wherein R<sub>1</sub> is E<sub>1</sub>CO (where  
2 E<sub>1</sub> is 4-hydroxy-phenyl, β-naphthylmethyl, or phenyl); A<sup>3</sup> is  
3 Tyr, Tyr(I), or Pal; A<sup>6</sup> is Val, Tle, Nle, Ile, or Leu; A<sup>8</sup> is p-  
4 F-Phe, β-Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-Phe; R<sub>3</sub> is NH<sub>2</sub>.

1 16. A compound of claim 15, wherein A<sup>3</sup> is Pal.

1 17. A compound of claim 14, of the formula

2 (H) (3-phenylpropionyl) -D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-  
 3 Nal-NH<sub>2</sub>;  
 4 (H) (3-phenylpropionyl) -D-Cys-Pal-D-Trp-Lys-Val-Cys-β-  
 5 Nal-NH<sub>2</sub>;  
 6 (H) (3-phenylpropionyl) -D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-  
 7 Nal-NH<sub>2</sub>;  
 8 (H) (3-phenylpropionyl) -D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-  
 9 Nal-NH<sub>2</sub>;  
 10 (H) (3-phenylpropionyl) -D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-  
 11 NH<sub>2</sub>;  
 12 (H) (3-phenylpropionyl) -D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-  
 13 NH<sub>2</sub>;  
 14 (H) (3-phenylpropionyl) -D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-  
 15 NH<sub>2</sub>;  
 16 (H) (3-phenylpropionyl) -D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-  
 17 NH<sub>2</sub>;  
 18 (H) (3-[2-naphthyl]propionyl) -D-Cys-Tyr-D-Trp-Lys-Val-  
 19 Cys-β-Nal-NH<sub>2</sub>;  
 20 (H) (3-[2-naphthyl]propionyl) -D-Cys-Pal-D-Trp-Lys-Val-  
 21 Cys-β-Nal-NH<sub>2</sub>;  
 22 (H) (3-[2-naphthyl]propionyl) -D-Cys-Tyr-D-Trp-Lys-Thr-  
 23 Cys-β-Nal-NH<sub>2</sub>;  
 24 (H) (3-[2-naphthyl]propionyl) -D-Cys-Pal-D-Trp-Lys-Thr-  
 25 Cys-β-Nal-NH<sub>2</sub>;  
 26 (H) (3-[2-naphthyl]propionyl) -D-Cys-Tyr-D-Trp-Lys-Val-  
 27 Cys-Thr-NH<sub>2</sub>;  
 28 (H) (3-[2-naphthyl]propionyl) -D-Cys-Pal-D-Trp-Lys-Val-  
 29 Cys-Thr-NH<sub>2</sub>;  
 30 (H) (3-[2-naphthyl]propionyl) -D-Cys-Tyr-D-Trp-Lys-Thr-  
 31 Cys-Thr-NH<sub>2</sub>;  
 32 (H) (3-[2-naphthyl]propionyl) -D-Cys-Pal-D-Trp-Lys-Thr-  
 33 Cys-Thr-NH<sub>2</sub>;  
 34 (H) (3-[p-hydroxyphenyl]) -D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-  
 35 Nal-NH<sub>2</sub>;

36 (H) (3-naphthyl]propionyl) -D-Cys-Tyr-D-Trp-Lys-Abu-Cys-  
 37  $\beta$ -Nal-NH<sub>2</sub>;  
 38 (H) (3-naphthyl]propionyl) -D-Cys-Tyr-D-Trp-Lys-Abu-Cys-  
 39 Thr-NH<sub>2</sub>;  
 40 (H) (3-phenyl]propionyl) -D-Cys-Tyr-D-Trp-Lys-Abu-Cys- $\beta$ -  
 41 Nal-NH<sub>2</sub>; or  
 42 (H) (3-phenyl]propionyl) -D-Cys-Tyr-D-Trp-Lys-Abu-Cys-  
 43 Thr-NH<sub>2</sub>; or  
 44 a pharmaceutically acceptable salt thereof.

1 18. A compound of claim 2, wherein R<sub>3</sub>, together with  
 2 the carbonyl group of A<sup>8</sup> attached thereto, are reduced to form  
 3 H, lower alkyl, or hydroxy lower alkyl.

1 19. A compound of claim 18, wherein A<sup>1</sup> is the D- or L-  
 2 isomer of  $\beta$ -Nal, o-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>,  
 3 NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>,  
 4 NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>,  
 5 NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl,  
 6 Tyr(I), Bta, Bip, Npa, or Pal; A<sup>3</sup> is  $\beta$ -Nal, o-X-Phe (where X  
 7 is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe (where X is  
 8 H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe (where X is H,  
 9 OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe, Trp, Dip, 2-Pal,  
 10 Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A<sup>6</sup> is Thr,  
 11 Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle,  $\beta$ -Ala, Gaba,  
 12 or Val; and A<sup>8</sup> is the D- or L-isomer of Thr, Dip, F<sub>5</sub>-Phe, p-X-  
 13 Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), o-X-  
 14 Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-  
 15 Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), Igl,  
 16 Tyr(Bzl), or  $\beta$ -Nal.

1 20. A compound of claim 19, wherein A<sup>1</sup> is the D- or  
 2 L-isomer of  $\beta$ -Nal, Phe, p-F-Phe, Trp, p-Cl-Phe, or p-CN-Phe;  
 3 A<sup>3</sup> is Tyr, Tyr(I), or Pal; A<sup>6</sup> is Val, Tle, Nle, Ile, or Leu; A<sup>8</sup>  
 4 is p-F-Phe,  $\beta$ -Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-Phe; R<sub>1</sub> is

5 H, CH<sub>3</sub>CO, 4-(2-hydroxyethyl)-1-piperazinyllacetyl, or 4-(2-  
6 hydroxyethyl)-1-piperizineethanesulfonyl; R<sub>2</sub> is H, and R<sub>3</sub>,  
7 together with the carboxy group of A<sup>8</sup> attached thereto, are  
8 reduced to form H or CH<sub>3</sub>OH.

1 21. A compound of claim 20, wherein A<sup>3</sup> is Pal.

1 22. A compound of claim 19, of the formula:

2 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R-(2-  
3 hydroxymethyl)-3-hydroxy)propylamide;

4 (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R-(2-  
5 hydroxymethyl)-3-hydroxy)propylamide;

6 (H) (4-(2-hydroxyethyl)-1-piperazinyllacetyl)-β-Nal-D-  
7 Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R-(2-hydroxymethyl)-3-  
8 hydroxy)propylamide;

9 (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-  
10 Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R-(2-hydroxymethyl)-3-  
11 hydroxy)propylamide;

12 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R, 3R-(2-  
13 hydroxymethyl)-3-hydroxy)propylamide;

14 (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R, 3R-(2-  
15 hydroxymethyl)-3-hydroxy)propylamide;

16 (H) (4-(2-hydroxyethyl)-1-piperazinyllacetyl)-β-Nal-D-  
17 Cys-Pal-D-Trp-Lys-Val-Cys-2R, 3R-(2-hydroxymethyl)-3-  
18 hydroxy)propylamide;

19 (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-  
20 Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R, 3R-(2-hydroxymethyl)-3-  
21 hydroxy)propylamide;

22 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R-(2-  
23 hydroxymethyl)-3-hydroxy)propylamide;

24 (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R-(2-  
25 hydroxymethyl)-3-hydroxy)propylamide;

26 (H) (4-(2-hydroxyethyl)-1-piperazinyllacetyl)-β-Nal-D-  
27 Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R-(2-hydroxymethyl)-3-  
28 hydroxy)propylamide;

29 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - $\beta$ -  
 30 Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R- (2-hydroxymethyl) -3-  
 31 hydroxy) propylamide;  
 32 H<sub>2</sub>- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R- (2-  
 33 hydroxymethyl) -3-hydroxy) propylamide;  
 34 (H) (CH<sub>3</sub>CO) - $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R- (2-  
 35 hydroxymethyl) -3-hydroxy) propylamide;  
 36 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - $\beta$ -Nal-D-  
 37 Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R- (2-hydroxymethyl) -3-  
 38 hydroxy) propylamide;  
 39 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - $\beta$ -  
 40 Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R- (2-hydroxymethyl) -3-  
 41 hydroxy) propylamide;  
 42 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R- (2-  
 43 hydroxymethyl) -3-hydroxy) propylamide;  
 44 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R- (2-  
 45 hydroxymethyl) -3-hydroxy) propylamide;  
 46 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-  
 47 Tyr-D-Trp-Lys-Val-Cys-2R,3R- (2-hydroxymethyl) -3-  
 48 hydroxy) propylamide;  
 49 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) Phe-  
 50 D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R- (2-hydroxymethyl) -3-  
 51 hydroxy) propylamide;  
 52 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R- (2-  
 53 hydroxymethyl) -3-hydroxy) propylamide;  
 54 H(CH<sub>3</sub>CO) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R- (2-  
 55 hydroxymethyl) -3-hydroxy) propylamide;  
 56 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-  
 57 Pal-D-Trp-Lys-Val-Cys-2R,3R- (2-hydroxymethyl) -3-  
 58 hydroxy) propylamide;  
 59 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) Phe-  
 60 D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R- (2-hydroxymethyl) -3-  
 61 hydroxy) propylamide;  
 62 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R- (2-  
 63 hydroxymethyl) -3-hydroxy) propylamide;

64 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R- (2-  
 65 hydroxymethyl) -3-hydroxy) propylamide;  
 66 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-  
 67 Tyr-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-  
 68 hydroxy) propylamide;  
 69 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) Phe-  
 70 D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-  
 71 hydroxy) propylamide;  
 72 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R, 3R- (2-  
 73 hydroxymethyl) -3-hydroxy) propylamide;  
 74 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R, 3R- (2-  
 75 hydroxymethyl) -3-hydroxy) propylamide;  
 76 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-  
 77 Pal-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-  
 78 hydroxy) propylamide;  
 79 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) Phe-  
 80 D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-  
 81 hydroxy) propylamide;  
 82 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R- (2-  
 83 naphthyl) ethylamide;  
 84 (H) (CH<sub>3</sub>CO) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R- (2-  
 85 naphthyl) ethylamide;  
 86 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-  
 87 Cys-Tyr-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;  
 88 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) -β-  
 89 Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;  
 90 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R- (2-  
 91 naphthyl) ethylamide;  
 92 (H) (CH<sub>3</sub>CO) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R- (2-  
 93 naphthyl) ethylamide;  
 94 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-  
 95 Cys-Pal-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;  
 96 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) -β-  
 97 Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;

98 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)  
 99 ethylamide;  
 100 (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-  
 101 naphthyl)ethylamide;  
 102 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
 103 Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;  
 104 (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-  
 105 Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;  
 106 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-  
 107 naphthyl)ethylamide;  
 108 (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-  
 109 naphthyl)ethylamide;  
 110 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
 111 Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;  
 112 (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-  
 113 Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;  
 114 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-  
 115 naphthyl)ethylamide;  
 116 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-  
 117 naphthyl)ethylamide;  
 118 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-  
 119 Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;  
 120 (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-  
 121 D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;  
 122 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)  
 123 ethylamide;  
 124 (H) (CH<sub>3</sub>CO) Phe-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-  
 125 naphthyl)ethylamide;  
 126 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-  
 127 Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;  
 128 (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-  
 129 D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;  
 130 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)  
 131 ethylamide;

132 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-  
 133 naphthyl) ethylamide;  
 134 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-  
 135 Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;  
 136 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) Phe-  
 137 D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;  
 138 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-  
 139 naphthyl) ethylamide;  
 140 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-  
 141 naphthyl) ethylamide;  
 142 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-  
 143 Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;  
 144 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) Phe-  
 145 D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;  
 146 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R- (2-  
 147 naphthyl) ethylamide;  
 148 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R- (2-  
 149 naphthyl) ethylamide;  
 150 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R, 3R- (2-  
 151 hydroxymethyl) -3-hydroxy) propylamide; or  
 152 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R, 3R- (2-  
 153 hydroxymethyl) -3-hydroxy) propylamide; or  
 154 a pharmaceutically acceptable salt thereof.

1 23. A compound of claim 1, wherein A<sup>2</sup> is a D-aromatic  
 2 amino acid or a D-aliphatic amino acid, A<sup>7</sup> is an aromatic  
 3 amino acid or an aliphatic amino acid, and A<sup>4</sup> is D-Trp.

1 24. A compound of claim 23, wherein A<sup>1</sup> is an L- amino  
 2 acid and A<sup>2</sup> is a D-aromatic amino acid.

1 25. A compound of claim 24, wherein A<sup>1</sup>, A<sup>3</sup>, and A<sup>7</sup>  
 2 independently, is β-Nal, o-X-Phe (where X is H, OH, CH<sub>3</sub>, halo,  
 3 OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe (where X is H, OH, CH<sub>3</sub>, halo,  
 4 OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe (where X is H, OH, CH<sub>3</sub>, halo,



5 OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His,  
6 Igl, Tyr(I), Bta, Bip, Npa, or Pal; A<sup>2</sup> is D-β-Nal, D-o-X-Phe  
7 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-p-X-Phe  
8 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-m-X-Phe  
9 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-F<sub>5</sub>-Phe,  
10 D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-  
11 Bta, D-Bip, D-Npa, or D-Pal; A<sup>6</sup> is Thr, Ser, Tle, Thr(Bzl),  
12 Abu, Ala, Ile, Leu, Gly, Nle, β-Ala, Gaba, or Val; and A<sup>8</sup> is  
13 the D- or L-isomer of Thr, Dip, F<sub>5</sub>-Phe, p-X-Phe (where X is H,  
14 OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), o-X-Phe (where X is H,  
15 OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe (where X is H,  
16 OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), Igl, Tyr(Bzl), or β-Nal.

1           26. A compound of claim 25, wherein A<sup>1</sup> is β-Nal or  
2 Phe, A<sup>2</sup> is D-Cpa or D-Phe; A<sup>3</sup> is Phe or Tyr; A<sup>6</sup> is Abu, Thr, or  
3 Val; A<sup>7</sup> is Phe; and A<sup>8</sup> is Thr; R<sub>1</sub> is H, CH<sub>3</sub>CO, 4-(2-  
4 hydroxyethyl)-1-piperazinyllacetyl, or 4-(2-hydroxyethyl)-1-  
5 piperizineethanesulfonyl; R<sub>2</sub> is H; and R<sub>3</sub> is NH<sub>2</sub>.

1           27.    A compound of claim 25 of the formula:  
 2           H<sub>2</sub>-Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
 3           H<sub>2</sub>-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
 4           H<sub>2</sub>-Phe-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
 5           H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
 6           (H) (CH<sub>3</sub>CO) - β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
 7           (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
 8 Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
 9           (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - β-  
 10 Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
 11           H<sub>2</sub>-β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
 12           (H) (CH<sub>3</sub>CO) - β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
 13           (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
 14 Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
 15           (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - β-  
 16 Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
 17           H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
 18           (H) (CH<sub>3</sub>CO) - β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
 19           (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
 20 Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
 21           (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - β-  
 22 Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
 23           H<sub>2</sub>-β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
 24           (H) (CH<sub>3</sub>CO) - β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
 25           (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
 26 Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
 27           (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - β-  
 28 Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
 29           H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>;  
 30           (H) (CH<sub>3</sub>CO) - β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>;  
 31           (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
 32 Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>; or  
 33           (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - β-  
 34 Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>;  
 35           H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>; or

36 H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>; or  
37 a pharmaceutically acceptable salt thereof.

1 28. A compound of claim 23, wherein A<sup>1</sup> is a D-amino  
2 acid and A<sup>2</sup> is a D-aromatic amino acid.

1 29. A compound of claim 28, wherein A<sup>1</sup> and A<sup>2</sup>,  
2 independently, is D-β-Nal, D-o-X-Phe (where X is H, OH, CH<sub>3</sub>,  
3 halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-p-X-Phe (where X is H, OH, CH<sub>3</sub>,  
4 halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-m-X-Phe (where X is H, OH, CH<sub>3</sub>,  
5 halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-F<sub>5</sub>-Phe, D-Trp, D-Dip, D-2-Pal,  
6 D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-Bta, D-Bip, D-Npa, or D-  
7 Pal; A<sup>3</sup> and A<sup>7</sup>, independently, is β-Nal, o-X-Phe (where X is H,  
8 OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe (where X is H,  
9 OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe (where X is H,  
10 OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe, Trp, Dip, 2-Pal,  
11 His, Igl, Tyr(I), Bta, Bip, Npa, Tyr(Bzl), or Pal; A<sup>6</sup> is Thr,  
12 Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, β-Ala, Gaba,  
13 or Val; and A<sup>8</sup> is the D- or L-isomer of Thr, Dip, F<sub>5</sub>-Phe, p-X-  
14 Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), o-X-  
15 Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-  
16 Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), Igl,  
17 Tyr(Bzl), or β-Nal.

1 30. A compound of claim 29, wherein A<sup>1</sup> is D-β-Nal or  
2 D-Phe; A<sup>2</sup> is D-Cpa or D-Phe; A<sup>3</sup> is Phe or Tyr; A<sup>6</sup> is Thr or  
3 Val; A<sup>7</sup> is Phe; and A<sup>8</sup> is Thr; R<sub>1</sub> is H, CH<sub>3</sub>CO, 4-(2-  
4 hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-  
5 piperizineethanesulfonyl; R<sub>2</sub> is H; and R<sub>3</sub> is NH<sub>2</sub>.

1 31. A compound of claim 29 of the formula:  
2 H<sub>2</sub>-D-β-Nal-D-Cpa-Phe-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
3 H<sub>2</sub>-D-β-Nal-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
4 H<sub>2</sub>-D-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
5 H<sub>2</sub>-D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>; or  
6 H<sub>2</sub>-D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>; or  
7 a pharmaceutically acceptable salt thereof.